全文获取类型
收费全文 | 539040篇 |
免费 | 34564篇 |
国内免费 | 665篇 |
专业分类
耳鼻咽喉 | 7277篇 |
儿科学 | 17883篇 |
妇产科学 | 14346篇 |
基础医学 | 89044篇 |
口腔科学 | 15026篇 |
临床医学 | 46351篇 |
内科学 | 98588篇 |
皮肤病学 | 12658篇 |
神经病学 | 38642篇 |
特种医学 | 19489篇 |
外国民族医学 | 77篇 |
外科学 | 80671篇 |
综合类 | 8584篇 |
一般理论 | 121篇 |
预防医学 | 40282篇 |
眼科学 | 12626篇 |
药学 | 41804篇 |
中国医学 | 1025篇 |
肿瘤学 | 29775篇 |
出版年
2018年 | 5327篇 |
2016年 | 4533篇 |
2015年 | 4957篇 |
2014年 | 6678篇 |
2013年 | 10329篇 |
2012年 | 13995篇 |
2011年 | 15469篇 |
2010年 | 8895篇 |
2009年 | 8422篇 |
2008年 | 14800篇 |
2007年 | 15881篇 |
2006年 | 16038篇 |
2005年 | 15492篇 |
2004年 | 15001篇 |
2003年 | 14322篇 |
2002年 | 14140篇 |
2001年 | 24895篇 |
2000年 | 25940篇 |
1999年 | 21262篇 |
1998年 | 5757篇 |
1997年 | 4960篇 |
1996年 | 5245篇 |
1995年 | 4814篇 |
1994年 | 4486篇 |
1992年 | 16176篇 |
1991年 | 16778篇 |
1990年 | 16870篇 |
1989年 | 16181篇 |
1988年 | 14940篇 |
1987年 | 14791篇 |
1986年 | 13971篇 |
1985年 | 13348篇 |
1984年 | 9886篇 |
1983年 | 8447篇 |
1982年 | 4690篇 |
1981年 | 4365篇 |
1979年 | 9663篇 |
1978年 | 7033篇 |
1977年 | 5918篇 |
1976年 | 5750篇 |
1975年 | 6552篇 |
1974年 | 7810篇 |
1973年 | 7296篇 |
1972年 | 7110篇 |
1971年 | 6805篇 |
1970年 | 6287篇 |
1969年 | 5994篇 |
1968年 | 5651篇 |
1967年 | 5099篇 |
1966年 | 4548篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Andrea von Berg Renate Engelstätter Predrag Minic Miodrag Sréckovic Maria Luz Garcia Garcia Tadeusz Lato Jan H. Vermeulen Stefan Leichtl Stefan Hellbardt Thomas D. Bethke 《Pediatric allergy and immunology》2007,18(5):391-400
Ciclesonide is an onsite-activated inhaled corticosteroid (ICS) for the treatment of asthma. This study compared the efficacy, safety and effect on quality of life (QOL) of ciclesonide 160 microg (ex-actuator; nominal dose 200 microg) vs. budesonide 400 microg (nominal dose) in children with asthma. Six hundred and twenty-one children (aged 6-11 yr) with asthma were randomized to receive ciclesonide 160 microg (ex-actuator) once daily (via hydrofluoroalkane metered-dose inhaler and AeroChamber Plus spacer) or budesonide 400 microg once daily (via Turbohaler) both given in the evening for 12 wk. The primary efficacy end-point was change in forced expiratory volume in 1 s (FEV1). Additional measurements included change in daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events. Both ciclesonide and budesonide increased FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication after 12 wk vs. baseline. The non-inferiority of ciclesonide vs. budesonide was demonstrated for the change in FEV1 (95% confidence interval: -75, 10 ml, p = 0.0009, one-sided non-inferiority, per-protocol). In addition, ciclesonide and budesonide showed similar efficacy in improving asthma symptoms, morning PEF, use of rescue medication and QOL. Ciclesonide was superior to budesonide with regard to increases in body height (p = 0.003, two-sided). The effect on the hypothalamic-pituitary-adrenal axis was significantly different in favor of ciclesonide treatment (p < 0.001, one-sided). Both ciclesonide and budesonide were well tolerated. Ciclesonide 160 microg once daily and budesonide 400 microg once daily were effective in children with asthma. In addition, in children treated with ciclesonide there was significantly less reduction in body height and suppression of 24-h urinary cortisol excretion compared with children treated with budesonide after 12 wk. 相似文献
992.
993.
There exists a constant need for a dental curing light that works reliably and conveniently in the general practitioner's office and can be used effectively for all the different curing procedures. Due to the need for improved physical properties of resin based composites (RBCs) and less stress at the marginal interface, light curing units (LCUs) experienced significant advances in the past years. The dental industry has focused on reducing the curing time by developing higher intensity curing lights and by altering the resin composition and photo-initiator concentration. As a result the dentist can now choose from a vast variety of curing lights, light intensities and curing methods. This article presents a review of the advances in light curing units and curing techniques, as well as the scientific principles that guided past developments and that will influence future advances. 相似文献
994.
995.
Tod B Sloan Celia I Kaye William R Allen Brian E Magness Steven A Wartman 《Academic medicine》2005,80(11):994-1004
Changes in the education, research, and health care environments have had a major impact on the way in which medical schools fulfill their missions, and mission-based management approaches have been suggested to link the financial information of mission costs and revenues with measures of mission activity and productivity. The authors describe a simpler system, termed Mission-Aligned Planning (MAP), and its development and implementation, during fiscal years 2002 and 2003, at the School of Medicine at the University of Texas Health Science Center at San Antonio, Texas. The MAP system merges financial measures and activity measures to allow a broad understanding of the mission activities, to facilitate strategic planning at the school and departmental levels. During the two fiscal years mentioned above, faculty of the school of medicine reported their annual hours spent in the four missions of teaching, research, clinical care, and administration and service in a survey designed by the faculty. A financial profit or loss in each mission was determined for each department by allocation of all departmental expenses and revenues to each mission. Faculty expenses (and related expenses) were allocated to the missions based on the percentage of faculty effort in each mission. This information was correlated with objective measures of mission activities. The assessment of activity allowed a better understanding of the real costs of mission activities by linking salary costs, assumed to be related to faculty time, to the missions. This was a basis for strategic planning and for allocation of institutional resources. 相似文献
996.
997.
998.
999.
The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. 总被引:16,自引:0,他引:16
A C Ogus B Yoldas T Ozdemir A Uguz S Olcen I Keser M Coskun A Cilli O Yegin 《The European respiratory journal》2004,23(2):219-223
Toll-like receptor 2 (TLR2), a member of the Toll-like receptor family, plays an important role in recognition of, and subsequent immune response activation against, mycobacteria. The genetic polymorphism of TLR2 (arginine to glutamine substitution at residue 753 (Arg753Gln)) has been associated with a negative influence on TLR2 function, which may, in turn, determine the innate host response to mycobacteria. The aim of the present study was to investigate the Arg753Gln single nucleotide polymorphism of the TLR2 gene in tuberculosis (TB) patients compared to healthy controls. A retrospective case/control study was carried out. The Arg753Gln polymorphism of the TLR2 gene was studied in 151 TB patients compared to 116 ethnically and age-matched healthy control subjects. The TLR2 polymorphism (adenine (A) allele) was observed in 17.9 and 7.7% of TB patients and controls, respectively. When the ratios of the three genotypes were compared between the two groups, the AA genotype was found to be more significantly associated with TB. Allele frequencies for guanine (G) and A were found to be 0.95 and 0.05 in the control group and 0.86 and 0.14 in the TB patient group, respectively. The risk of developing TB disease was increased 6.04- and 1.60-fold for carriers of the AA and GA genotypes, respectively. In conclusion, the present data suggest that the arginine to glutamine substitution at residue 753 polymorphism of the Toll-like receptor 2 gene influences the risk of developing tuberculosis. 相似文献
1000.
K. F. Tait J. E. Collins J. M. Heward I. Eaves H. Snook J. A. Franklyn A. H. Barnett J. A. Todd M. Maranian A. Compston S. Sawcer S. C. L. Gough 《Diabetic medicine》2004,21(3):267-270
Aims The Type 1 diabetes susceptibility locus, IDDM2, has been mapped to a variable number of tandem repeats (VNTR) region 5′ upstream of the insulin (INS) and insulin‐like growth factor (IGF2) genes on chromosome 11p15. The function of the VNTR is uncertain; however, it may influence the thymic expression of the insulin gene and affect the development of immune self‐tolerance. The aim of this study was to investigate whether the INS VNTR region is a Type 1 diabetes‐specific locus or acting as a general autoimmunity gene. Methods We genotyped the INS‐IGF2 VNTR [using the surrogate INS?23 HphI single nucleotide polymorphism (SNP)] in 823 Graves’ disease (GD)/multiple sclerosis (MS) families, 1433 GD/MS patients and 837 healthy control subjects. Results We found no evidence of excess transmission of the allele associated with Type 1 diabetes to individuals affected by GD or MS within the families. Analysis of the case–control dataset showed no genotypic or allelic difference between the two populations. Conclusions These data suggest that the INS‐IGF2 VNTR is acting as a Type 1 diabetes‐specific susceptibility gene rather than as an influence on general autoimmunity. 相似文献